As of Wednesday close, Statera Biopharma Inc.’s (NASDAQ:STAB) stock traded at $0.10. The average number of shares traded per day over the past five days has been 1,697,320 shares. 2 times new highs have been achieved over the past 5 days, with a $0.0030 gain in that time frame. In the last twenty days, the average volume was 1,638,040, while in the previous 50 days, it was 3,857,468.
Since last month, STAB stock retreated -25.55%. Shares of the company fell to $0.0945 on 11/10/22, the lowest level in the past month. A 52-week high of $3.60 was reached on 01/03/22 after having rallying from a 52-week low of $0.09. Since the beginning of this year, STAB’s stock price has dropped by -95.48% or -$2.1960, and marked a new high 1 time. However, the stock has declined by -97.11% since its 52-week high.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
In the recent quarter, Statera Biopharma Inc.’s quick ratio stood at 0.10, while its current ratio was 0.10, showing that the company is not able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 67.90% percent. Based on annual data, STAB earned $1.0 million in gross profit and brought in $1.49 million in revenue.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. STAB’s revenue rose 64.18% to $0.77 million during the quarter, while net income inched up to $0.67 million. During the quarter, the company generated -$1.35 million in EBITDA. The liabilities of Statera Biopharma Inc. were 22.92 million at the end of its most recent quarter, and its total debt was $7.12 million. The value of shareholders’ equity is $54.66 million.
This quick technical analysis looks at Statera Biopharma Inc.’s (STAB) price momentum. With a historical volatility rate of 128.06%, the RSI 9-day stood at 41.07% on 23 November.
With respect to its five-day moving average, the current Statera Biopharma Inc. price is up by +2.97% percent or $0.0030. At present, STAB shares trade -30.15% below its 20-day simple moving average and -62.06% percent below its 100-day simple moving average. However, the stock is currently trading approximately -40.23% below its SMA50 and -89.23% below its SMA200.
Stochastic coefficient K was 12.55% and Stochastic coefficient D was 11.89%, while ATR was 0.0164. Given the Stochastic reading of 21.44% for the 14-day period, the RSI (14) reading has been calculated as 41.25%.
Statera Biopharma Inc. (STAB) has been rated Hold by analysts. According to 0 brokerage firms, STAB is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Statera Biopharma Inc. stock as buy, with 0 recommending it as overweight.
With a median target price of $40.00, the current consensus forecast for the stock is $40.00 – $40.00. Based on these forecasts, analysts predict Statera Biopharma Inc. (STAB) will achieve an average price target of $40.00.